Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis

doi:10.1155/2021/9930059

科研成果详情

题名	Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis
作者	Lu, Jianglong1; Cai, Lin1; Wu, Zerui1; Lin, Weiwei 1; Xu, Jiadong 1; Zhu, Zhangzhang 1; Wang, Chengde1; Li, Qun1; Su, Zhipeng1,2
发表日期	2021-08-31
发表期刊	INTERNATIONAL JOURNAL OF ENDOCRINOLOGY 影响因子和分区
语种	英语
原始文献类型	Review
其他关键词	DOPAMINE AGONIST WITHDRAWAL ; TERM-FOLLOW-UP ; TRANSSPHENOIDAL SURGERY ; PITUITARY-ADENOMAS ; ENDOSCOPIC SURGERY ; PROGNOSTIC-FACTORS ; SURGICAL-TREATMENT ; HEART-DISEASE ; PROLACTINOMAS ; CABERGOLINE
摘要	Objective. Dopamine agonists (DAs) are recommended as the first-line treatment for prolactinomas; however, tumour recurrence after drug withdrawal remains a clinical problem. Recent studies have reported high remission rates via surgery in microprolactinomas. The aim of this systematic review and meta-analysis was to compare the clinical result of DA treatment with surgery as initial therapy in patients with treatment-naive microprolactinoma. Methods. A comprehensive literature search for studies and reports regarding microprolactinoma patients treated with DAs and/or surgery published between January 1970 and November 2020 was conducted using four electronic databases (PubMed, Embase, Google Scholar, and the Cochrane Library). Clinical treatment outcome was evaluated by the biochemical remission of serum prolactin level to normal after treatment. The I-2 statistic was used to quantify heterogeneity. Pooled data were analysed according to a random effect model. Results. Eighteen studies with 661 patients were included for analysis. The DA treatment group achieved a higher remission rate at >= 12 months follow-up (96% vs. 86%; P=0.019). Surgery showed a higher remission rate than the DA treatment group after the treatment withdrawal (78% vs. 44%; P=0.003). Patients with preoperative prolactin level of <= 200 ng/mL had a higher remission rate than patients with preoperative prolactin level of >200 ng/mL (92% vs. 40%; P=0.029). Conclusion. Surgery showed a high remission rate in treatment-naive microprolactinoma patients after treatment withdrawal and may be an alternative first-line treatment strategy in addition to DAs, particularly in patients with a preoperative prolactin level of <= 200 ng/mL.
资助项目	Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LY19C070002, LQ17C060002]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81801367]
出版者	HINDAWI LTD
出版地	LONDON
ISSN	1687-8337
EISSN	1687-8345
卷号	2021 页码:9930059
DOI	10.1155/2021/9930059
页数	11
WOS类目	Endocrinology & Metabolism
WOS研究方向	Endocrinology & Metabolism
WOS记录号	WOS:000695291200001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	34504526
PMC记录号	PMC8423556
SCOPUSEID	2-s2.0-85115097094
通讯作者地址	[Su, Zhipeng]Department of Neurosurgery,First Affiliated Hospital,Wenzhou Medical University,Wenzhou,325000,China
Scopus学科分类	Endocrinology, Diabetes and Metabolism;Endocrinology;Endocrine and Autonomic Systems
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/15129
专题	附属第一医院
通讯作者	Su, Zhipeng
作者单位	1.Department of Neurosurgery,First Affiliated Hospital,Wenzhou Medical University,Wenzhou,325000,China; 2.Department of Neurosurgery,Wencheng Country People's Hospital,Wenzhou,325000,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Lu, Jianglong,Cai, Lin,Wu, Zerui,et al. Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis[J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY,2021,2021:9930059.
APA	Lu, Jianglong., Cai, Lin., Wu, Zerui., Lin, Weiwei., Xu, Jiadong., ... & Su, Zhipeng. (2021). Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2021, 9930059.
MLA	Lu, Jianglong,et al."Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis".INTERNATIONAL JOURNAL OF ENDOCRINOLOGY 2021(2021):9930059.